News

5‑Nitro‑1H‑pyrrolo[2,3‑b]pyridine (5‑nitro‑7‑azaindole, CAS: 101083‑92‑5) is a nitrogen‑rich fused bicyclic heterocycle with the molecular formula C₇H₅N₃O₂ and a molecular weight of 163.13 g/mol. Its structure — a pyrrolo[2,3‑b]pyridine (7‑azaindole) core bearing a nitro group at the 5‑position — represents one of the most privileged and extensively deployed scaffolds in modern kinase inhibitor drug discovery. The 7‑azaindole ring system is a well‑established purine bioisostere that closely mimics adenine, the natural ligand of ATP‑binding sites in protein kinases, providing a versatile platform for the rational design of potent and selective kinase‑targeted therapeutics.

This compound has become a strategically critical intermediate across multiple high‑value pharmaceutical development pipelines. It is used as a key building block for the synthesis of cell division cycle 7 (Cdc7) kinase inhibitors, which represent a promising novel class of cancer therapies targeting DNA replication initiation; as a critical intermediate in the preparation of 4‑anilinoquinazoline anticancer agents; and as a versatile scaffold for synthesising a wide array of kinase inhibitors targeting FGFR, ATM, PLK4, GSK‑3β, AAK1 and other clinically validated oncology and CNS drug targets.

Core Application Fields and Market Demand

Market demand for 5‑nitro‑7‑azaindole is strongly concentrated in three major sectors: Cdc7 kinase inhibitor development (≈50‑55 % of total demand), FGFR inhibitor development (≈25‑30 %), and other kinase‑targeted drug discovery programmes (≈15‑20 %), including PLK4, ATM, GSK‑3β, AAK1 and PFTAIRE protein kinase 2 (PFTK1) inhibitors.

Cdc7 Kinase Inhibitor Development (≈50‑55 %). Cdc7 is a serine/threonine kinase that plays an essential role in the initiation of DNA replication and is overexpressed in many cancer types, making it an attractive target for the development of novel anti‑cancer therapies. 5‑Nitro‑7‑azaindole serves as a key reagent in the synthesis of Cdc7 kinase inhibitors, which are being actively investigated as a promising new class of oncology drugs.

FGFR Inhibitor Development (≈25‑30 %). The nitro‑substituted pyrrolo[2,3‑b]pyridine scaffold has been shown to be a potent inhibitor of fibroblast growth factor receptors (FGFRs). Given that FGFRs play an essential role in a wide range of tumours and that abnormal activation of the FGFR signalling pathway is associated with cancer progression, targeting FGFRs represents an attractive therapeutic strategy. Derivatives built on this scaffold have demonstrated the ability to inhibit breast cancer cell proliferation and induce apoptosis.

Kinase Inhibitor Library Synthesis (≈15‑20 %). The 5‑nitro‑7‑azaindole core provides a versatile starting point for constructing diverse kinase inhibitor libraries. Researchers have exploited this scaffold to develop selective inhibitors targeting PLK4 for cancer therapy, GSK‑3β for the treatment of Alzheimer‘s disease, AAK1 for antiviral applications, ATM for antitumour therapy, and PFTK1 for heart‑related and cancer pathways.

The global market for 7‑azaindole derivatives is expected to grow at a CAGR of 7‑9 % in China alone, with increasing demand from both domestic and international pharmaceutical markets. The 5‑nitro‑7‑azaindole segment continues to expand as the compound finds more applications in targeted cancer therapy programmes and kinase inhibitor screening libraries.

Major Market Participants

The global supply system for 5‑nitro‑7‑azaindole follows a pattern of specialised fine chemical and pharmaceutical intermediate manufacturers, primarily in China, India, Europe and North America, serving both small‑scale R&D and large‑scale industrial production. The compound is generally supplied as a yellow to off‑white solid with purity ranging from 97 % to ≥98 % by HPLC, with a melting point of approx. 280 °C and should be stored under refrigeration at 2‑8 °C.

Shanghai XinChem Co., Ltd. (XinChem) has established a reliable, fully quality‑controlled supply chain for high‑purity 5‑nitro‑7‑azaindole (CAS 101083‑92‑5). Our product meets rigorous pharmaceutical intermediate specifications — purity 97‑98 % (HPLC), yellow to off‑white solid, molecular weight 163.13 g/mol, MDL MFCD06659682, HS code 2933399990.

Regional Market Dynamics

Global demand for 5‑nitro‑7‑azaindole shows a distinct regional pattern: North America and Europe lead in Cdc7/FGFR inhibitor R&D and high‑purity pharmaceutical intermediate consumption, Asia‑Pacific is the largest and fastest‑growing region for production and intermediate supply, and Latin America and Middle East/Africa are emerging growth regions.

North America (USA & Canada) accounts for the largest share of high‑purity Cdc7 and FGFR inhibitor intermediate consumption, with the most extensive pipeline of targeted cancer therapies and the highest density of biotech start‑ups. Europe follows, led by Germany, Switzerland and the United Kingdom — centres of excellence in kinase inhibitor discovery. Asia‑Pacific is the most dynamic region; China has emerged as the dominant manufacturing hub, producing high‑purity 5‑nitro‑7‑azaindole at competitive prices, and the Chinese market alone is expanding at a CAGR of 7‑9 %.

Future Outlook

The market outlook for 5‑nitro‑7‑azaindole is tied to four core drivers: (1) the expanding global pipeline of Cdc7 and FGFR kinase inhibitors for targeted cancer therapy; (2) increasing research into 7‑azaindole‑based therapeutics for Alzheimer‘s disease and antiviral applications; (3) the rapid growth of Asian CRO/CDMO sectors supplying intermediates to global pharmaceutical companies; and (4) the privileged status of the 7‑azaindole scaffold as a first‑choice platform in fragment‑based drug discovery (FBDD) programmes.

Enterprises should focus on securing high‑purity (≥98 %) production capabilities, maintaining rigorous impurity documentation for pharmaceutical regulatory filings, and building long‑term supply partnerships with API manufacturers and CROs.

Shanghai XinChem Co., Ltd. (XinChem)

As a world‑leading supplier of pharmaceutical intermediates and heterocyclic building blocks, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the targeted therapeutics, oncology drug discovery and kinase inhibitor intermediate industries. Relying on core advantages in multi‑step heterocyclic synthesis, purification and quality assurance, we provide high‑quality 5‑Nitro‑7‑azaindole (5‑Nitro‑1H‑pyrrolo[2,3‑b]pyridine, CAS 101083‑92‑5) to global customers. Its 7‑azaindole core serves as a purine bioisostere, making it an ideal starting point for Cdc7 kinase inhibitors, FGFR inhibitors, selective PLK4 inhibitors for cancer therapy, GSK‑3β inhibitors for Alzheimer’s disease, AAK1 inhibitors with antiviral activity, ATM inhibitors for antitumour therapy, and diverse targeted drug discovery programmes.

1. Technical Advantages

High Purity & Consistency: Our product achieves purity 97‑98 % (HPLC), yellow to off‑white solid, molecular weight 163.13 g/mol, moisture <0.5 %.
Low Impurity Profile: Strict control of residual solvents, heavy metals (≤10 ppm, ICH Q3D compliant), and related substances.
Batch‑to‑Batch Uniformity: Rigorous analytical testing (HPLC, NMR) guarantees consistent quality, enabling reproducible yields in pharmaceutical production.

2. Product Advantages

Versatile Cdc7/FGFR Kinase Scaffold: Directly used in the synthesis of Cdc7 kinase inhibitors (for novel cancer therapy targeting DNA replication initiation), 4‑anilinoquinazoline anticancer agents, FGFR inhibitors (potent against breast cancer), selective PLK4 inhibitors, GSK‑3β inhibitors, AAK1 inhibitors with antiviral activity, and ATM inhibitors with in vivo antitumour activity.
Scalable Synthesis: Well‑developed synthetic routes with demonstrated multi‑kilogram scalability via metal‑free cycloisomerisation.
Flexible Packaging Options: 5 g, 10 g, 25 g, 50 g, 100 g, 500 g glass bottles (R&D); 1 kg HDPE containers (pilot); 5 kg, 10 kg, 25 kg fibre drums (industrial). Full custom packaging available.
Reliable Supply Chain: Annual capacity 100‑500 kg, with dedicated temperature‑controlled warehousing (2‑8 °C, light‑protected) and just‑in‑time delivery.

3. Application Fields

Pharmaceutical Intermediates: Key building block for Cdc7 kinase inhibitors (targeting DNA replication), 4‑anilinoquinazoline anticancer agents, FGFR inhibitors, PLK4 inhibitors, GSK‑3β inhibitors, AAK1 inhibitors with antiviral activity, ATM inhibitors, and PFTK1 inhibitors for oncology.
Oncology Drug Discovery: Construction of diverse azaindole‑based kinase inhibitor libraries for targeted cancer therapy targeting breast, lung, pancreatic, colorectal, bladder and brain cancers.
CNS & Neurological Drug Discovery: GSK‑3β inhibitors for Alzheimer‘s disease therapy.
Inflammatory & Antiviral Research: AAK1 inhibitors for broad‑spectrum antiviral activity.

4. Service Support
Our technical team provides full impurity profiling (HPLC purity, residual solvents, heavy metals), custom purification to any desired specification, and complete regulatory documentation (Certificate of Analysis, Technical Data Sheet, Safety Data Sheet, REACH compliance, TSCA certification, DMF support for pharmaceutical customers). We also offer custom synthesis of 7‑azaindole derivatives, cold‑chain logistics and just‑in‑time delivery.

5. Why Choose XinChem

Professionalism: 20+ years in the pharmaceutical intermediate and heterocyclic synthesis industry.
Flexibility: Tailored to customer purity specifications, packaging sizes and regulatory documentation requirements.
Cost‑effectiveness: High purity at competitive industrial pricing.

Post time: May-17-2026

The Privileged Heterocyclic Scaffold for Cdc7/FGFR Kinase Inhibitors and Targeted Cancer Therapy: 5‑Nitro‑7‑azaindole (CAS 101083‑92‑5)